Sharp Therapeutics Provides Update on Non-Brokered Private Placement and Grant of Options
Pennsylvania and Toronto, Ontario--(Newsfile Corp. - December 19, 2025) - Sharp Therapeutics Corp. (TSXV: SHRX) (OTCQB: SHRXF) ("Sharp" or the "Company"), is pleased to announce that the non-brokered private placement to raise gross proceeds of not less than US$10,000,000 (the "Offering") previously announced on October 14, 2025 has been updated. The placement will consist of common shares in the capital of the Company priced at not less than US$2.50 per share. The Company expects the...
2025-12-19 5:05 PM EST
Sharp Therapeutics Corp. Reports Third Quarter 2025 Results and Development Update
Pennsylvania and Toronto, Ontario--(Newsfile Corp. - November 26, 2025) - Sharp Therapeutics Corp. (TSXV: SHRX) (OTCQB: SHRXF) ("Sharp" or the "Company"), announces the release of its condensed interim consolidated financial statements for the three and nine months ended September 30, 2025, and related management discussion and analysis. All dollar figures are in United States dollars, unless otherwise stated. Scott Sneddon, Sharp's Chief Executive Officer, stated: "Our Q3 financial results...
2025-11-26 7:35 AM EST
Sharp Therapeutics Arranges Non-Brokered Private Placement
Pennsylvania and Toronto, Ontario--(Newsfile Corp. - October 14, 2025) - Sharp Therapeutics Corp. (TSXV: SHRX) (OTCQB: SHRXF) ("Sharp" or the "Company"), is pleased to announce that it is arranging a non-brokered private placement to raise gross proceeds of not less than US$10,000,000 (the "Offering"). The placement will consist of common shares in the capital of the Company priced at not less than US$2.50 per share. The Company expects the offering to close in the fourth quarter of 2025. The...
2025-10-14 11:22 AM EDT
Sharp Therapeutics Corp. Reports Second Quarter 2025 Results and Expands Market Presence with Listing On OTCQB
Pennsylvania and Toronto, Ontario--(Newsfile Corp. - August 29, 2025) - Sharp Therapeutics Corp. (TSXV: SHRX) (OTCQB: SHRXF) ("Sharp" or the "Company") announces the release of its condensed interim consolidated financial statements for the three and six months ended June 30, 2025, and related management discussion and analysis. All dollar figures are in United States dollars, unless otherwise stated. The Company also announces that its common shares are now trading under the symbol "SHRXF"...
2025-08-29 5:25 PM EDT
Sharp Therapeutics Corp. Engages Rho Inc. to Help Advance Compounds into Clinical Trials for Gaucher Disease
Pennsylvania and Toronto, Ontario--(Newsfile Corp. - July 29, 2025) - Sharp Therapeutics Corp. (TSXV: SHRX) ("Sharp" or the "Company"), a preclinical-stage biotechnology company developing small molecule therapies to treat genetic diseases, today announced that it has engaged Rho, Inc. ("Rho"), a global contract research organization (CRO), to support Sharp's preparation and planned submission of its Investigational New Drug Application ("IND") to the U.S. Food and Drug Administration (the...
2025-07-29 5:05 PM EDT
Sharp Therapeutics Corp. Announces Results from Annual Meeting of Shareholders
Pennsylvania and Toronto, Ontario--(Newsfile Corp. - July 21, 2025) - Sharp Therapeutics Corp. (TSXV: SHRX) ("Sharp" or the "Company"), a pre-clinical biotechnology company developing small molecule therapies to treat genetic diseases, is pleased to announce the voting results from its annual general meeting of shareholders held on July 18, 2025 (the "Meeting"). All nominees set forth in the Company's management information circular dated June 10, 2025 (the "Circular") were elected as...
2025-07-21 5:05 PM EDT
Sharp Therapeutics Corp. Reports First Quarter 2025 Results
Pennsylvania and Toronto, Ontario--(Newsfile Corp. - May 22, 2025) - Sharp Therapeutics Corp. (TSXV: SHRX) ("Sharp" or the "Company"), a pre-clinical-stage biotechnology company developing small molecule therapies to treat genetic diseases, announces the release of its condensed interim consolidated financial statements for the three months ended March 31, 2025, and related management discussion and analysis. All dollar figures are in United States dollars, unless otherwise stated. Scott...
2025-05-22 5:45 PM EDT
Sharp Therapeutics Corp. Nominates Clinical Candidate for Gaucher's Disease
Pennsylvania and Toronto, Ontario--(Newsfile Corp. - May 13, 2025) - Sharp Therapeutics Corp. (TSXV: SHRX) ("Sharp" or the "Company"), a pre-clinical-stage biotechnology company developing small molecule therapies to treat genetic diseases, announces that it has nominated a small molecule compound from its GBA program for clinical development in Gaucher's disease. Sharp has launched its clinical development program for Gaucher's disease by nominating a compound from the SEL-148,721 series of...
2025-05-13 5:05 PM EDT
STX PARTNERS LLP and Newlin Investment Co. Exercise Warrants of Sharp Therapeutics Corp.
Pennsylvania and Toronto, Ontario--(Newsfile Corp. - April 21, 2025) - Sharp Therapeutics Corp. (TSXV: SHRX) ("Sharp" or the "Company"), a pre-clinical-stage biotechnology company developing small molecule therapies to treat hereditary disorders, is pleased to announce that STX PARTNERS LLP ("STX") and Newlin Investment Company ("NIC") have each exercised their respective common share purchase warrants of the Company (the "Warrants") for aggregate gross proceeds to the Company of US$2.5M. The...
2025-04-21 5:05 PM EDT
Sharp Therapeutics Corp. Completes Share Consolidation
Pennsylvania and Toronto, Ontario--(Newsfile Corp. - January 27, 2025) - Sharp Therapeutics Corp. (TSXV: SHRX) ("Sharp" or the "Company"), a pre-clinical stage biotechnology company specializing in small molecule drugs to treat genetic diseases, is pleased to announce the successful completion of its previously announced consolidation of its common shares (the "Common Shares") on the basis of one (1) post-consolidation Common Share for every ten (10) pre-consolidation Common Shares, with any...
2025-01-27 8:24 AM EST
Sharp Therapeutics Corp. Announces Share Consolidation
Pennsylvania and Toronto, Ontario--(Newsfile Corp. - January 16, 2025) - Sharp Therapeutics Corp. (TSXV: SHRX) ("Sharp" or the "Company"), a pre-clinical stage biotechnology company specializing in small molecule drugs to treat genetic diseases, announces that its board of directors has approved a consolidation (the "Consolidation") of the Company's issued and outstanding common shares (the "Common Shares") on the basis of ten (10) pre-consolidation shares for one (1) post-consolidated share....
2025-01-16 8:53 AM EST
Sharp Therapeutics Corp. Announces Completion of Qualifying Transaction
Toronto, Ontario--(Newsfile Corp. - December 12, 2024) - Sharp Therapeutics Corp. (TSXV: EVP.P) ("Sharp Therapeutics"), formerly EVP Capital Inc. ("EVP Capital"), an Ontario corporation is pleased to announce the successful completion of its qualifying transaction by way of a reverse takeover of Sharp Edge Labs, Inc. ("Sharp Edge") under the policies of the TSX Venture Exchange (the "TSXV"). Pursuant to a statutory plan of arrangement under the Business Corporations Act (Ontario) (the...
2024-12-12 1:36 PM EST
EVP Capital Announces Delivery of Management Information Circular in Connection with Annual General and Special Meeting and Encourages Shareholders to Access Meeting Materials Electronically
Toronto, Ontario--(Newsfile Corp. - November 25, 2024) - EVP Capital Inc., an Ontario corporation (TSXV: EVP.P) ("EVP Capital") has delivered and is in the process of continuing to effect delivery of the management information circular (the "Circular") and related materials for the annual general and special meeting (the "Meeting") of holders of common shares ("EVP Shares") of EVP Capital ("EVP Shareholders") to be held December 6, 2024. At the Meeting, EVP Shareholders will be asked, among...
2024-11-25 8:30 AM EST
EVP Capital Files its Proxy Circular for Upcoming Shareholder Meeting to Approve its Plan of Arrangement Transaction with Sharp Edge
Toronto, Ontario--(Newsfile Corp. - November 1, 2024) - EVP Capital Inc., an Ontario corporation (TSXV: EVP.P) ("EVP Capital"), is pleased to announced that, in accordance with National Instrument 51-102 - Continuous Disclosure Obligations, it has filed its management information circular (the "Circular") and related proxy materials in respect of its annual and special meeting of shareholders of EVP Capital to be held on December 6, 2024 at 12:00 p.m. (Toronto time) (the "Meeting") to approve...
2024-11-01 6:32 PM EDT
EVP Capital Receives Conditional Approval from TSX Venture Exchange on Qualifying Transaction with Sharp Edge and Court Approval to Call Shareholder Meeting
Toronto, Ontario--(Newsfile Corp. - October 21, 2024) - EVP Capital Inc., an Ontario corporation (TSXV: EVP.P) ("EVP Capital"), is pleased to announced that is has received conditional approval from the TSX Venture Exchange ("TSXV") for its previously announced statutory plan of arrangement under section 182 of the Business Corporations Act (Ontario) whereby SEL AcquisitionCo Inc. ("Merger Sub"), a Delaware incorporated wholly-owned subsidiary of EVP Capital, will acquire all of the issued...
2024-10-21 8:30 AM EDT
EVP Capital Announces Receipt of Interim Order in Respect of Proposed Arrangement with Sharp Edge and Provides Details of Shareholder Meeting
Toronto, Ontario--(Newsfile Corp. - July 30, 2024) - EVP Capital Inc., an Ontario corporation (TSXV: EVP.P) ("EVP Capital"), is pleased to announce that the Ontario Superior Court of Justice (Commercial List) (the "Court") has granted an interim order (the "Interim Order") in connection with the previously announced statutory plan of arrangement under section 182 of the Business Corporations Act (Ontario) (the "OBCA"), pursuant to which, subject to the satisfaction or waiver of all applicable...
2024-07-30 4:01 PM EDT
EVP Capital Announces Agreement for Proposed Qualifying Transaction
Toronto, Ontario--(Newsfile Corp. - July 2, 2024) - EVP Capital Inc., an Ontario corporation (TSXV: EVP.P) ("EVP Capital"), is pleased to announce that it has entered into a definitive arrangement agreement and plan of merger dated June 28, 2024 (the "Arrangement Agreement") by and among EVP Capital, Sharp Edge Labs, Inc., a Delaware corporation ("Sharp Edge") and SEL AcquisitionCo Inc. ("Merger Sub"), a Delaware incorporated wholly-owned subsidiary of EVP Capital. The Arrangement Agreement...
2024-07-02 8:30 AM EDT